Physician profile
John W Park
NPI 1053375444
$558,481.04
in general payments reported to CMS, 2019-2025
10 companies · $124K in 2025
The $124K reported for 2025 was more than what 98% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63K · 2020: $5,731 · 2021: $27K · 2022: $136K · 2023: $136K · 2024: $67K · 2025: $124K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $279K · Travel and Lodging: $39K · Food and Beverage: $6,963 · Consulting Fee: $2,668.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $279,245.00 |
| Travel and Lodging | $38,587.20 |
| Food and Beverage | $6,962.63 |
| Consulting Fee | $2,667.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $205,845.28 | 2021-2025 | Enhertu, Datroway |
| Daiichi Sankyo INC. | $144,575.95 | 2022-2025 | Enhertu, Datroway |
| Genentech USA, INC. | $105,678.40 | 2019-2022 | |
| Gilead Sciences, INC. | $85,092.22 | 2021-2025 | Trodelvy |
| Pfizer INC. | $8,533.07 | 2019-2022 | |
| Immunomedics, INC. | $4,525.00 | 2020 | |
| Genentech, INC. | $3,960.00 | 2019 | |
| Allergan, INC. | $148.15 | 2022 | |
| Abbott Laboratories | $103.58 | 2021 | |
| Novo Nordisk INC | $19.39 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.